"Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment" (PROTECT-HF)

Bradycardia Clinical Trial

— PROTECT-HF  

Official title:

Physiological vs Right Ventricular Pacing Outcome Trial Evaluated for bradyCardia Treatment

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05815745
• Other study ID #: 22HH7931
• Status: Recruiting
• Phase: N/A
• Start date: June 5, 2023
• Est. completion date: December 4, 2029

Study information

• Verified date: March 2024
• Source: Imperial College London
• Contact: Zachary Whinnett
• Phone: +447749576830
• Email: z.whinnett[@]imperial.ac.uk
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The PROTECT-HF multi-centre randomised controlled trial will compare two different pacing approaches for treating patients with slow heart rates. In it the investigators will compare a long-standing standard approach for pacing; right ventricular pacing, with a new form of pacing, physiological pacing (His and Left bundle area pacing) in 2600 patients.

Patients will be allocated at random to receive either right ventricular pacing or physiological pacing. Endpoint measurements will be undertaken at baseline, and at six-monthly intervals post-randomisation. Treatment allocation will be blinded to the endpoint assessor and the patient.

Recruitment and pacemaker implantation will be carried out at each participating centre. The primary analysis will be intention to treat. The investigators will also perform an on-treatment analysis.

2048 patients are needed to detect the expected effect size with 85% power. A total of 2600 patients will be recruited to allow for patient drop-out and crossover.

500-patient sub-study will assess within patient, and between groups, echocardiographic changes over a 24-month period to try and improve mechanistic understanding of PICM (Pacing Induced Cardiomyopathy).

Description:

Patients entering the study will attend for implantation of a pacemaker device and be randomised to either right ventricular pacing or physiological pacing.

Patients at sites participating in echo sub-study will be informed of and given opportunity to consent to echo sub-study, this will be optional to them, even if they have consented to the main study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 2600
• Est. completion date: December 4, 2029
• Est. primary completion date: December 4, 2029
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

We will recruit patients who are referred for clinically indicated pacemaker implantation

Inclusion Criteria:

1. Adults aged over 18 with left ventricular ejection fraction >35% and one or more of the following guideline based ventricular pacing indications:

1. Permanent or intermittent 3rd degree AV block

2. Permanent or intermittent Mobitz type II AV block

3. First Degree AV block with a pacing indication

4. Slow chronic Atrial Fibrillation or Proposed AV node ablation

5. Bifasciular block with a pacing indication

6. Trifasicular block with a pacing indication

7. Wenckebach with a pacing indication

Exclusion Criteria:

1. Patients who are likely to only need occasional ventricular pacing, i.e. those with isolated sick sinus syndrome.

2. Pregnant women.

3. Unable to provide informed consent.

4. Those with comorbidity leading to a life expectancy <1year.

Related Conditions & MeSH terms

• Bradycardia
• His Bundle Pacing
• Left Bundle Branch Area Pacing
• Pacing
• Right Ventricular Pacing

Intervention

Device:
• Pacemaker - Physiological pacing
The approach for physiological pacing will be either His bundle pacing or left bundle pacing at the operator's discretion. If both of these are not achieved biventricular pacing will be performed.
• Pacemaker - Right Ventricular pacing
Right ventricular pacing (apical or septal lead locations as per the implanting physicians' normal practice).

Locations

Country	Name	City	State
United Kingdom	University Hospital Dorset	Bournemouth
United Kingdom	Royal SUSSEX County Hospital	Brighton
United Kingdom	St Richard's Hospital	Chichester
United Kingdom	University Hospital Coventry	Coventry
United Kingdom	Croydon	Croydon
United Kingdom	Victoria Hospital	Fife Keith
United Kingdom	Medway Maritime Hospital	Gillingham
United Kingdom	Wycombe Hospital	High Wycombe
United Kingdom	Forth Valley Royal Hospital	Larbert
United Kingdom	Leeds Teaching Hospital	Leeds
United Kingdom	Glenfield Hospital	Leicester
United Kingdom	Liverpool Heart and Chest Hospital	Liverpool
United Kingdom	Hammersmith Hospital	London
United Kingdom	Kettering Hospital	London
United Kingdom	King's College Hospital	London
United Kingdom	Royal Free London/ Barnet Hospital	London
United Kingdom	St Bartholomew's Hospital	London
United Kingdom	Watford General Hospital	London
United Kingdom	James Cook Hospital	Middlesbrough
United Kingdom	King's Mill Hospital	Nottingham
United Kingdom	Nottingham City Hospital	Nottingham
United Kingdom	John Radcliffe Hospital	Oxford
United Kingdom	Royal Berkshire	Reading
United Kingdom	East Surrey	Redhill
United Kingdom	Rotherham General Hospital	Rotherham
United Kingdom	Northern General	Sheffield
United Kingdom	Southampton	Southampton
United Kingdom	Morriston Hospital	Swansea
United Kingdom	Great Western	Swindon
United Kingdom	UHS Worthing	Worthing

Sponsors (2)

Lead Sponsor	Collaborator
Imperial College London	British Heart Foundation

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Mortality	Death, any cause	From date of consent, until date of death from any cause, assessed up until 78 months.
Primary	Heart Failure Morbidity	Adjudicated unplanned heart failure acute care (hospital admissions or ambulatory diuretic therapy i.e. diuretic lounge visit).	From date of consent, assessed up until 78 months, or death from any cause, whichever came first.
Secondary	Incidence of clinically indicated upgrade to conventional biventricular pacing (CRT device)		From date of randomisation until the date of first documented incident of device upgrade, or death from any cause, whichever came first, assessed up to 78 months.
Secondary	Patient quality of life assessed via questionnaires (EQ-5D-5L) EQ-5D is the name of the instrument and is not an acronym.	The EQ-5D-5L consists of 2 pages: the EQ-5D descriptive system and the EQ 'visual analogue scale' (EQ VAS).; The descriptive system is made up of 5 sections: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems.; A High score on the descriptive section means a worse health outcome. A Low score on the descriptive section means a better health outcome. A value set is required to convert the outcomes into scores.; The EQ VAS records the patient's self-rated health on a vertical visual analogue scale, where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'. The VAS can be used as a quantitative (numerical) measure of health outcome that reflect the patient's own judgement.; A high score on the VAS means a better outcome. A low score on the VAS means a worse outcome.	From date of consent, assessed up to 78 months or until death of any cause, whichever came first.
Secondary	Patient symptoms assessed on a scale of 0-100 monthly	This questionnaire will be sent to participants on a monthly basis for the duration of the study, 78 months from one month post pacemaker implant until end of study (78 months) or death from any cause, whichever came first.	From one month after device implant date, assessed up to 78 months or until death of any cause, whichever came first.
Secondary	Safety endpoints: Device infections (requiring device extraction), pacing thresholds, need for lead revision or reimplantation, generator change, haematoma and pneumothorax		From device implant date, assessed up to 78 months or until death of any cause, whichever came first.
Secondary	Pacemaker derived endpoints: a) Atrial fibrillation (duration >6minutes) b) Ventricular arrhythmia incidence c) Daily patient activity (hours stratified by device vendor)		From device implant date, assessed up to 78 months or until death of any cause, whichever came first.
Secondary	Patient quality of life assessed via questionnaires '36-Item Short Form Health Survey' (SF-36)	A high score defines a more favourable health state. Range 0 to 100.	From date of consent, assessed up to 78 months or until death of any cause, whichever came first.
Secondary	Echo Sub-Study Endpoint: Left Ventricular End Systolic Volume (LVESV) (>10mls) within group differences	Within group differences of Left Ventricular End Systolic Volume (>10mls) for differences according to treatment allocation.	From baseline echocardiogram (0 to 6 weeks post pacemaker implant) to follow-up echocardiogram (24±1 months post pacemaker implant).
Secondary	Echo Sub-Study Endpoint: Ejection Fraction (EF) within patient changes	Within patient changes in Ejection Fraction will be assessed for differences according to treatment allocation.	From baseline echocardiogram (0 to 6 weeks post pacemaker implant) to follow-up echocardiogram (24±1 months post pacemaker implant).
Secondary	Echo Sub-Study Endpoint: Left Ventricular End Systolic Volume (LVESV) (>10mls) within patient changes	Within patient changes of Left Ventricular End Systolic Volume (>10mls) for differences according to treatment allocation	From baseline echocardiogram (0 to 6 weeks post pacemaker implant) to follow-up echocardiogram (24±1 months post pacemaker implant).
Secondary	Echo Sub-Study Endpoint: Ejection Fraction (EF) within group differences	Within group differences in Ejection Fraction will be assessed for differences according to treatment allocation.	From baseline echocardiogram (0 to 6 weeks post pacemaker implant) to follow-up echocardiogram (24±1 months post pacemaker implant).